Aim: The precise selection of patients for ACT is critical but there remain no validated molecular tools which are prognostic for relapse or predictive of benefit from ACT. Methods: LACE-Bio, based on the LACE (Lung Adjuvant Cisplatin Evaluation) meta-analysis project, includes a fully annotated database and tissue bank from 4 randomised trials comparing ACT to non-treated control (IALT(1), ANITA(2), NCIC CTG JBR-10 (3) and CALGB 9633(4). It contains ∼1500 samples, including frozen tissue (JBR.10). Histochemical/immunohistochemical (HC) biomarkers shown in one trial to have a significant prognostic and/or predictive effect on overall survival, were cross-validated in the 3 other trials; when only a trend (T) for such effects was observed we performed a pooled analysis combining all 4 trials. All statistical analyses were conducted by the meta-analysis unit at Gustave Roussy. Biomarker assays for validation/pooled analyses were in general conducted by the group reporting the original biomarker results Results: Numerous issues were encountered during the attempted validation of promising assays, including method of fixation, storage, the use of TMAs vs. sections, stored vs. fresh sections, and reagent/antibody batches. Despite meticulous methodology, the majority of the promising biomarkers (other than mutations) could not be confirmed as of value. 
